MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 901–1,000 of 1,006
Role of redoximiRs in fibrogenesis
Fierro‐Fernández, M., Miguel, V., & Lamas, S. (2015) · Redox Biology · doi:10.1016/j.redox.2015.11.006 · Cited by 52
“TGF-β and ROS induce miR-9-5p e self-limit its pro-fibrogenic action. miR-9-5p inhibits the transformation of fibroblasts in different organs.”
BackgroundmiR-21 is associated with fibrosis and right ventricular failure
Reddy, S., Hu, D., Zhao, M., Blay, E., Sandeep, N., Ong, S., Jung, G., Kooiker, K. B., Coronado, M. J., Fajardo, G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91625 · Cited by 51
Liu, Z., Liang, X., Li, X., Liu, X., Zhu, M., Gu, Y., & Zhou, P. (2019) · Toxicology Research · doi:10.1039/c9tx00019d · Cited by 47
MicroRNA-99b-3p promotes angiotensin II-induced cardiac fibrosis in mice by targeting GSK-3β
Yu, Y., Zhang, Y., Ding, Y.-Q., Bi, X., Yuan, J., Zhou, H., Wang, P., Zhang, L., & Ye, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0498-z · Cited by 47
“For example, it was reported that miR-21 had no detectable influence on the mRNA level of Spry1 in CFs but resulted in strong inhibition of Spry1 protein expression [12].”
BackgroundLiao, Y., Li, H., Cao, H., Dong, Y., Gao, L., Liu, Z., Ge, J., & Zhu, H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00750-6 · Cited by 48
Jia, S., Ma, W.-D., Zhang, C., Zhang, Y., Yao, Z., Quan, X.-H., Guo, X., & Wang, C. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108154 · Cited by 49
The Roles of microRNAs in the Cardiovascular System
Nappi, F., Singh, S., Jitendra, V., Alzamil, A., & Schoell, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814277 · Cited by 52
“In animal models, miR-21 inhibitors have exhibited efficacy in preventing cardiac fibrosis or neointimal formation [12].”
MicroRNAs in cardiovascular ageing
Seeger, T., & Boon, R. A. (2015) · The Journal of Physiology · doi:10.1113/jp270557 · Cited by 53
Liu, F., Zheng, S., Liu, T., Liu, Q., Liang, M., Li, X., Sheyhidin, I., Lu, X., & Liu, W. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1693-8 · Cited by 46
Riedel, S., Radzanowski, S., Bowen, T. S., Werner, S., Erbs, S., Schuler, G. C., & Adams, V. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314541036 · Cited by 47
“These results on miR-21 are contradictory to what is reported for heart tissue, where increased miR-21 expression is related to increased fibrosis and cardiac dysfunction.(21,22) This discrepancy is possibly due to the different cell types analysed – endothelial cells vs.”
ResultPathogenesis of Arrhythmias in a Model of CKD
Hsueh, C., Chen, N. X., Lin, S., Chen, P., Gattone, V. H., Allen, M. R., Fishbein, M. C., & Moe, S. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013121343 · Cited by 52
Xu, Z., Ramachandran, S., Gunasekaran, M., Zhou, F., Trulock, E. P., Kreisel, D., Hachem, R. R., & Mohanakumar, T. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.03.021 · Cited by 51
Non-coding RNAs as modulators of the cardiac fibroblast phenotype
Piccoli, M.-T., Bär, C., & Thum, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.023 · Cited by 50
Self-citationMicroRNA-328, a Potential Anti-Fibrotic Target in Cardiac Interstitial Fibrosis
Du, W., Liang, H., Gao, X., Li, X., Zhang, Y., Pan, Z., Li, C., Wang, Y., Liu, Y., Yuan, W., et al. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447793 · Cited by 46
Fabiani, I., Scatena, C., Mazzanti, C. M., Conte, L., Pugliese, N. R., Franceschi, S., Lessi, F., Menicagli, M., Martino, A. D., Pratali, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1011-9 · Cited by 52
“A regulatory role for miRNA-21 has been evidenced in LV myocardial remodeling induced by hemodynamic stress [17, 18].”
Goldberg, L., Tirosh‐Wagner, T., Vardi, A., Abbas, H., Pillar, N., Shomron, N., Nevo‐Caspi, Y., & Paret, G. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9814-0 · Cited by 49
“Furthermore, the inhibition of miR-21 prevented fibrosis in murine cardiac allografts [37], as well as in mice with pressure-overload model silencing of miR21 by an antagonist-reduced cardiac ERK–MAP kinase activity, inhibited interstitial fibrosis and attenuated cardiac dysfunction [38].”
BackgroundAn Overview of the Cytoskeleton-Associated Role of PDLIM5
Huang, X., Qu, R., Ouyang, J., Zhong, S., & Dai, J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00975 · Cited by 46
The Pathophysiology of Cardiac Hypertrophy and Heart Failure
Stansfield, W. E., Ranek, M. J., Pendse, A. A., Schisler, J. C., Wang, S., Pulinilkunnil, T., & Willis, M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405206-2.00004-1 · Cited by 61
Cardiac Physiology of Aging: Extracellular Considerations
Horn, M. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140063 · Cited by 48
MicroRNAs: Novel Players in Aortic Aneurysm
Fu, X., Zhou, Y., Cheng, Z., Liao, X., & Zhou, X. (2015) · BioMed Research International · doi:10.1155/2015/831641 · Cited by 48
“It is highly expressed in VSMC and ECs and targets phosphatase and tensin homolog (PTEN) [44, 45], programmed cell death 4 (PDCD4) [46], sprouty-1 (SPRY1) [47], and B cell lymphoma 2 (BCL2) [45].”
BackgroundInfluentialEdwards, J. K., Pasqualini, R., Arap, W., & Calin, G. A. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9179-5 · Cited by 51
“miR-21 Unknown Initially found to be highly expressed in hypertrophic cardiomyocytes, but conflicting reports have surfaced [15, 23–25] Table 1 Select miRNAs exhibiting differential expression patterns in hypertrophy 272 J.”
BackgroundResultRegulation of cardiac microRNAs induced by aerobic exercise training during heart failure
de Souza, R. W. A., Fernández, G. J., Cunha, J. P. Q. C., Piedade, W. P., Soares, L. C., Castro, P. A. T. D. S., de Campos, D. H. S., Okoshi, K., Cicogna, A. C., Dal‐Pai‐Silva, M., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2014 · Cited by 51
Liu, M., Liu, R., Wu, H., Li, Y., Su, M.-X., Dong, M.-N., Zhang, W., & Qian, C. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-0991-6 · Cited by 47
“Upregulation of miR-21 was observed in the cardiac fibroblasts of failing hearts and treatment with an miR-21 antagomir in amouse model of cardiac hypertrophy prevented interstitial fibrosis and improved cardiac function [40].”
BackgroundMicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?
Cavarretta, E., & Frati, G. (2016) · BioMed Research International · doi:10.1155/2016/2150763 · Cited by 47
“After the seminal studies on miR-21 by Thum [58], a key target in CV diseases would be reduction/inhibition ofmyocardial fibrosis associated with postischemic cardiopathy, drug-induced or primitive cardiomyopathies [59], but the question is far from being resolved yet [60, 61].”
Noncoding RNAs in Heart Failure
Dangwal, S., Schimmel, K., Foinquinos, A., Xiao, K., & Thum, T. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_99 · Cited by 46
“The very first miRNA to be identified to control cardiac fibrosis, miR-21, at the same time constitutes the most intensively studied pro-fibrotic miRNA, in regard to fibrosis development not only in the heart but also in the lung and kidney (Bao et al. 2014; Liu et al. 2010; Thum et al. 2008).”
BackgroundSelf-citationXiao, L., He, H., Ma, L.-L., Da, M., Cheng, S., Duan, Y., Wang, Q., Wu, H., Song, X., Duan, W., et al. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.01.006 · Cited by 47
Gómez-Verján, J. C., Vázquez-Martínez, E. R., Rivero-Segura, N. A., & Medina-Campos, R. H. (2018) · Human Genetics · doi:10.1007/s00439-018-1955-3 · Cited by 48
Myocardial reverse remodeling: how far can we rewind?
Gonçalves‐Rodrigues, P., Leite-Moreira, A. F., & Falcão‐Pires, I. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00696.2015 · Cited by 53
Zhao, G. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105387 · Cited by 45
Tan, J., Tong, B., Wu, Y., & Xiong, W. (2014) · Europe PMC (PubMed Central) · Cited by 44
MicroRNAs as Biomarkers for Myocardial Infarction
Salic, K., & Windt, L. J. D. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0238-z · Cited by 54
Up-regulation of MicroRNA-21 Mediates Isoflurane-induced Protection of Cardiomyocytes
Olson, J. M. G., Yan, Y., Bai, X., Ge, Z., Liang, M., Kriegel, A. J., Twaroski, D. M., & Bosnjak, Z. J. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000567 · Cited by 44
Yu‐Wai‐Man, C., & Khaw, P. T. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.983475 · Cited by 46
“Mice treated with miR-21 antisense probes were also protected from bleomycin-induced pulmonary fibrosis [54], and cardiac fibrosis induced by pressure overload [55].”
BackgroundSmall but smart: MicroRNAs orchestrate atherosclerosis development and progression
Santovito, D., Egea, V., & Weber, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.12.013 · Cited by 50
Induction of MiR-21 by Stereotactic Body Radiotherapy Contributes to the Pulmonary Fibrotic Response
Kwon, O.-S., Kim, K.-T., Lee, E., Kim, M., Choi, S.-H., Li, H., Fornace, A. J., Cho, J.-H., Lee, Y., Lee, J.-S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154942 · Cited by 46
“We therefore tested the ability of an anti-sense oligonucleotide to miR-21, which specifically inhibits miR-21, to delay the fibrotic response, finding that this anti-sense-miR21 was effective [15, 21, 42].”
BackgroundTherapeutic microRNAs in polycystic kidney disease
Yheskel, M., & Patel, V. (2017) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000333 · Cited by 44
Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?
Vestri, A., Pierucci, F., Frati, A., Monaco, L., & Meacci, E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00296 · Cited by 45
miRNAs in stem cell aging and age-related disease
Choi, S. W., Lee, J. Y., & Kang, K. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.013 · Cited by 62
Long non-coding RNA CHRF facilitates cardiac hypertrophy through regulating Akt3 via miR-93
Wo, Y., Guo, J., Li, P., Yang, H., & Wo, J. (2018) · Cardiovascular Pathology · doi:10.1016/j.carpath.2018.04.003 · Cited by 45
MicroRNA-135a inhibits cardiac fibrosis induced by isoproterenol via TRPM7 channel
Wu, Y. L., Liu, Y., Pan, Y., Lu, C., Xu, H., Wang, X., Liu, T., Feng, K., & Tang, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.157 · Cited by 44
Moccia, F. D., Lodola, F., Stadiotti, I., Pilato, C. A., Bellin, M., Carugo, S., Pompilio, G., Sommariva, E., & Maione, A. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163986 · Cited by 51
“It was also demonstrated that miR-21-5p inhibition leads to reduced cardiomyocyte fibrosis and dysfunction in regulating the ERK/MAP kinase signaling pathway [70].”
BackgroundA meta-analysis of microRNA expression profiling studies in heart failure
Gholaminejad, A., Zare, N., Dana, N., Shafie, D., Mani, A., & Javanmard, S. H. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10071-9 · Cited by 48
“Accordingly, the inhibition of miR-21 by specific antagomiR led to reduced hypertrophy and fibrosis [71].”
BackgroundThe Impact of microRNAs in Renin–Angiotensin-System-Induced Cardiac Remodelling
Adamcová, M., Kawano, I., & Šimko, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094762 · Cited by 46
Xue, C., Luo, M., Wang, L., Li, C., Hu, S., Yu, X., Yuan, P., & Wu, Z. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01856 · Cited by 44
Noncoding RNAs in Cardiac Hypertrophy and Heart Failure
Lu, P., Ding, F., Xiang, Y. K., Hao, L., & Zhao, M. (2022) · Cells · doi:10.3390/cells11050777 · Cited by 47
“However, miR-21 is upregulated in fibroblasts but not cardiomyocytes in the pressure-overloaded heart model [72].”
BackgroundThe Role of Epigenetics in the Fibrotic Processes Associated with Glaucoma
McDonnell, F. S., O'Brien, C. J., & Wallace, D. (2014) · Journal of Ophthalmology · doi:10.1155/2014/750459 · Cited by 45
Wu, X., Yin, J., Simpson, J., Kim, K.-H., Gu, S., Hong, J. H., Bayliss, P., Backx, P. H., Neel, B. G., & Araki, T. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00751-12 · Cited by 45
“Cardiac fibroblasts have also been implicated in hypertrophy pathogenesis (43, 48), and compared with their WT counterparts, neonatal D486N/D486N cardiac fibroblasts showed enhanced Mek/Erk activation in response to multiple agonists (Fig.”
ResultInhibition of HIPK2 protects stress-induced pathological cardiac remodeling
Zhou, Q., Meng, D., Li, F., Zhang, X., Liu, L., Zhu, Y., Liu, S., Xu, M., Deng, J., Lei, Z., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104274 · Cited by 45
García, R., Nistal, J. F., Merino, D., Price, N. L., Fernandez-Hernando, C. F., Beaumont, J., González, A., Hurlé, M. A., & Villar, A. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.006 · Cited by 43
Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure
Lai, K., Sanderson, J. E., Izzat, M. B., & Yu, C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.043 · Cited by 43
Chistiakov, D. A., Sobenin, I. A., & Orekhov, A. N. (2012) · Drug Delivery · doi:10.3109/10717544.2012.738436 · Cited by 47
“miR-21 OMe + 3′ cholesterol Mice Improvement of cardiac function, fibrosis reduction Thum et al. (2008)”
BackgroundInfluentialLiu, T., Shen, D., Xing, S., Chen, J., Yu, Z., WANG, J., Wu, B., Chi, H., Zhao, H., Liang, Z., et al. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1182 · Cited by 44
“Thum et al (13) reported that miR-21 is regulated by mitogen-activated protein kinase (MAPK)/extracellular signal related kinase (ERK) signaling in response to cardiac stress (1,12,14).”
Oury, C., Servais, L., Bouznad, N., Hego, A., Nchimi, A., & Lancellotti, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071120 · Cited by 43
“In different cell types isolated from failing hearts, miR-21 was predominantly upregulated in cardiac fibroblasts, and mediated protection from apoptosis, possibly through activation of extracellular signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK) signaling [56].”
Zhao, Y., Yuan, Y., & Qiu, C. (2016) · Medical Science Monitor · doi:10.12659/msm.896191 · Cited by 48
“Indeed, cardiac fibroblasts have a higher expression level of miR-29a3p, where it is implicated in atrial profibrillatory remodeling and activation of profibrotic pathways [29] in experimental models of heart failure [30].”
BackgroundGeng, X., Zhang, M., Lai, X., Tan, L., Liu, J., Yu, M., Deng, X., Hu, J., & Li, A. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800558 · Cited by 44
Hu, C., Sui, B., Liu, J., Dang, L., Chen, J., Zheng, C., Shi, S., Zhao, N., Dang, M., He, X., et al. (2021) · Small Methods · doi:10.1002/smtd.202100763 · Cited by 43
Rohm, T. V., Reis, F. C. G., Isaac, R., Murphy, C., Rocha, K. C. E., Bandyopadhyay, G. K., Gao, H., Libster, A. M., Zapata, R. C., Lee, Y. S., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01023-w · Cited by 52
Hmgb3 Is Regulated by MicroRNA-206 during Muscle Regeneration
Maciotta, S., Meregalli, M., Cassinelli, L., Parolini, D., Farini, A., Fraro, G. D., Gandolfi, F., Forcato, M., Ferrari, S., Gabellini, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043464 · Cited by 43
“importantly, their central role in gene-expression regulation was implicated in many human diseases [3,4,5,6,7,8] Regarding this, in the recent years many efforts were focused to finely characterize the role of miRNAs in myogenesis, so that now the miRNA biogenesis is considered necessary for proper muscle development…”
BackgroundMiR-21 inhibits c-Ski signaling to promote the proliferation of rat vascular smooth muscle cells
Li, J., Li, Z., Xie, H., Yang, T., & Yang, K. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.12.013 · Cited by 44
Epigenetic regulation of cardiac fibrosis
Tao, H., Shi, K., Yang, J., Huang, C., Liu, L., & Li, J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.03.024 · Cited by 44
Yang, K., Ku, Y.-C., Lovett, M., & Nerbonne, J. M. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.04.012 · Cited by 45
“Interestingly, miR-21, which has been shown to promote tissue fibrosis in pulmonary [35] and cardiac [36] disease, was upregulated in response to TAC, and this upregulation was attenuated with increased PI3Kα signaling (Figs.”
BackgroundInfluentialDrechsler, J., Grötzinger, J., & Hermanns, H. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043155 · Cited by 42
“Primary neonatal rat cardiac fibroblasts were prepared as described previously [46], but cultured in Medium 199 containing 10% FCS and kindly provided by Dr.”
MethodMicroRNAs Are Involved in End-Organ Damage During Hypertension
Heggermont, W., & Heymans, S. R. B. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.187104 · Cited by 44
“contribute to myocardial fibrosis by stimulating mitogenactivated protein kinase signaling in fibroblasts.(42) However, Thum et al(42) convincingly showed that inhibiting miR-21”
BackgroundCrippa, S., Nemir, M., Ounzain, S., Ibberson, M. R., Berthonneche, C., Sarre, A., Boisset, G., Maison, D., Harshman, K., Xénarios, I., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw031 · Cited by 42
Chen, Y., Xian, P.-F., Yang, L., & Wang, S. (2016) · BioMed Research International · doi:10.1155/2016/9279078 · Cited by 59
“reported thatmiR-21 could stimulateMAP kinase signaling in fibroblasts and cause cardiac fibroblast survival and cardiac remodeling [25].”
BackgroundLi, X., Zhao, Z., Gao, C., Rao, L., Hao, P., Jian, D., Li, W., Tang, H., & Li, M. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-100018 · Cited by 42
Liang, B., Xiao, T., Long, J., Liu, M., Li, Z., Liu, S., & Yang, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3191 · Cited by 47
“Thum et al found that the expression level of miR‑21 was significantly elevated in a heart failure model; however, silenced miR‑21 may alleviate myocardial fibrosis and improve heart function (59).”
Microtubule associated protein 4 phosphorylation leads to pathological cardiac remodeling in mice
Li, L., Zhang, Q., Zhang, X., Zhang, J., Wang, X., Ren, J. T., Jia, J., Zhang, D., Jiang, X., Zhang, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.017 · Cited by 42
“Pathological hypertrophy is closely associated with cardiac fibrosis [26,27].”
BackgroundMeta‐Analysis of the Potential Role of miRNA‐21 in Cardiovascular System Function Monitoring
Krzywińska, O., Bracha, M., Jeannière, C., Recchia, E., Kornatowska, K. K., & Kozakiewicz, M. (2020) · BioMed Research International · doi:10.1155/2020/4525410 · Cited by 42
“This mechanism regulates the survival of fibroblasts and the secretion of growth factor, controlling interstitial fibrosis and cardiac hypertrophy [37].”
BackgroundAryankalayil, M. J., Martello, S. E., Bylicky, M. A., Chopra, S., May, J. M., Shankardass, A., MacMillan, L., Sun, L. T., Sanjak, J. S., Vanpouille‐Box, C., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02998-w · Cited by 42
He, W., Wang, C., Mu, R., Liang, P., Huang, Z., Zhang, J., & Dong, L. (2017) · Oncogene · doi:10.1038/onc.2017.62 · Cited by 47
miR-21: a star player in cardiac hypertrophy
Duygu, B., & Martins, P. A. D. C. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv026 · Cited by 44
Liu, M., Long, X., Xu, J., Chen, M., Yang, H., Guo, X., Kang, J., Ouyang, Y., Luo, G., Yang, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106515 · Cited by 42
Khidr, E. G., Abulsoud, A. I., Doghish, A. A., El‐Mahdy, H. A., Ismail, A. M. A., Elballal, M. S., Sarhan, O. M., Mageed, S. S. A., Elsakka, E. G. E., Elkhawaga, S. Y., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154624 · Cited by 43
Ortega, R., Liu, B., & Persaud, S. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310777 · Cited by 49
Siddesha, J. M., Valente, A. J., Yoshida, T., Sakamuri, S. S. V. P., Delafontaine, P., Iba, H., Noda, M., & Chandrasekar, B. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.005 · Cited by 44
MicroRNAs in heart failure: Small molecules with major impact
Kalozoumi, G., Yacoub, M. H., & Sanoudou, D. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.30 · Cited by 43
“In particular, the increased miR-21 expression observed in human HF,(70) has been attributed mainly to fibroblasts using the TAC mouse model of HF.(84) Specifically, miR-21 is selectively upregulated in the fibroblasts of the failing heart and has been shown to target Spry1, a negative regulator of ERK-MAPK pathway, w…”
BackgroundMethodInfluentialCirculating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets
Wang, F., Chen, C., & Wang, D. W. (2014) · Frontiers of Medicine · doi:10.1007/s11684-014-0379-2 · Cited by 46
“In recent years, genetic gain- and loss-of-function studies have revealed the prominent roles of miRNAs in various cardiovascular disorders, including HF [108,109], cardiac hypertrophy and fibrosis [108,110], AMI [111], and angiogenesis, etc.”
Regulation of cardiac microRNAs by serum response factor
Zhang, X., Azhar, G., Helms, S. A., & Wei, J. Y. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-15 · Cited by 49
“In the failing heart, miR-21 levels are increased in fibroblasts where it inhibits sprouty homologue 1 (Spry1) and promotes fibrosis [16].”
BackgroundMungunsukh, O., & Day, R. M. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-01-0017 · Cited by 45
Ulm, S., Liu, W., Zi, M., Tsui, H., Chowdhury, S. K., Endo, S., Satoh, Y., Prehar, S., Wang, R., Cartwright, E. J., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.03.002 · Cited by 46
Liu, X., Hong, Q., Wang, Z., Yu, Y., Zou, X., & Xu, L. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215605586 · Cited by 42
“The role of miR-21 in fibrosis was first reported in myocardial disease.(20) Thum et al.”
BackgroundWu, K., Ye, C., Lin, L., Chu, Y., Ji, M., Dai, W., Zeng, X. Y., & Lin, Y. (2016) · Clinical Science · doi:10.1042/cs20160334 · Cited by 47
Liang, S., Cai, G., Duan, Z.-Y., Liu, S., Wu, J., Lv, Y., Hou, K., Li, Z., Zhang, X.-G., & Chen, X. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0482-0 · Cited by 41
“Recent studies reported a major role of miR-21 in mediating the pathogenic activation of lung and cardiac fibroblasts and, ultimately, fibrosis [12, 13].”
BackgroundThe feedback loop between miR-21, PDCD4 and AP-1 functions as a driving force for renal fibrogenesis
Sun, Q., Miao, J., Luo, J., Yuan, Q., Cao, H., Su, W., Zhou, Y., Jiang, L., Fang, L., Dai, C., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.202317 · Cited by 43
“Previous studies, including those from our laboratory, showed that miR-21 regulates lung, liver, kidney and heart fibrosis by enhancing the fibrogenic activity or by promoting the proliferation of interstitial fibroblasts (Hernandez-Gea and Friedman, 2011; Thum et al., 2008; Zhou et al., 2013).”
BackgroundResultMicroRNA‐574 regulates FAM210A expression and influences pathological cardiac remodeling
Wu, J., Subbaiah, K. C. V., Jiang, F., Hedaya, O. M., Mohan, A. M., Yang, T., Welle, K. A., Ghaemmaghami, S., Tang, W. H. W., Small, E. M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012710 · Cited by 46
MicroRNAs in Cardiovascular Diseases: Biology and Potential Clinical Applications
Kartha, R. V., & Subramanian, S. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9172-z · Cited by 49
“Recently, Thum and coworkers [116] validated miR-21 as a disease target for heart failure, which has therapeutic implications.”
BackgroundPrenatal inflammation exacerbates hyperoxia-induced functional and structural changes in adult mice
Velten, M., Britt, R. D., Heyob, K. M., Welty, S. E., Eiberger, B., Tipple, T. E., & Rogers, L. K. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00029.2012 · Cited by 43
“Furthermore, dysregulation of miRs has been linked to fibrosis in multiple organs, including the heart (52), kidney (8), and lung (12).”
Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy
Wang, Y., Li, M., Xu, L., Liu, J., Wang, D., Li, Q., Wang, L., Li, P., Chen, S., & Liu, T. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5977 · Cited by 42
“In addition, silencing of the miR‑21 gene inhibits the transduction of EPK‑MAPK signals, thus inhibiting the fibrosis and improving cardiac functions (31).”
Wei, Y., Yan, X., Yan, L., Hu, F., Ma, W., Wang, Y., Lu, S., Zeng, Q., & Wang, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7584 · Cited by 43
“Notably, the dysregulation of certain miRNAs regulates various fibrosis‑associated proteins to influence the development and progression of cardiac fibrosis (13,14).”
Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure
Poller, W. C., Hajjar, R. J., Schultheiss, H.-P., & Fechner, H. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq056 · Cited by 49
“Whereas the landmark papers that have elucidated the biological and pathogenic roles of this miRNA have used transgenic and knockout animals and viral vectors, the antagomir approach has shown impressive therapeutic potential, although its target is expressed in multiple organs.(29) It will be interesting to see which…”
BackgroundHepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
miR-21 and cardiac fibrosis: another brick in the wall?: Figure 1
Cavarretta, E., & Condorelli, G. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv184 · Cited by 41
“Strong evidence has also been obtained for miR-21 in cardiac fibrosis: it has been shown to promote fibroblast survival, growth factor secretion, and synthesis of collagens through regulation of the extracellular signal-regulated kinase–mitogen-activated protein kinase (ERK– MAPK) signalling pathway, via the inhibitio…”
BackgroundRinck, A., Preusse, M., Laggerbauer, B., Lickert, H., Engelhardt, S., & Theis, F. J. (2013) · RNA Biology · doi:10.4161/rna.24955 · Cited by 40
Self-citationMicroRNA Involvement in Immune Activation During Heart Failure
van de Vrie, M., Heymans, S. R. B., & Schroen, B. L. M. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6291-y · Cited by 44
“Here, it was identified as a critical regulator of the extracellular signal-regulated kinase-mitogen-activated protein kinase (ERK-MAPK) signaling pathway by inhibition of the protein sprouty homologue 1 (SPRY1) [100, 101].”
BackgroundPalayoor, S. T., John‐Aryankalayil, M., Makinde, A. Y., Falduto, M. T., Magnuson, S. R., & Coleman, C. N. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0623 · Cited by 42
“Interestingly, miR29 blocks fibrosis by inhibiting the expression of extracellular matrix components, whereas miR21 promotes fibrosis in SMCs after vascular injury by stimulating MAPK signaling (45).”
Background“Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases”
Alexander, M. S., & Kunkel, L. M. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-140058 · Cited by 44
“MicroRNA-21 was also shown to be significantly increased in expression in rodent models of myocardial disease, and activate ERK/MAPK signaling pathways in cardiac fibroblasts [52].”
BackgroundMicroRNA Expression Signature Is Altered in the Cardiac Remodeling Induced by High Fat Diets
Guedes, E. C., França, G. S., Lino, C. A., Koyama, F. C., Moreira, L. D. N., Alexandre, J. G., Barreto‐Chaves, M. L. M., Galante, P. A. F., & Diniz, G. P. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25280 · Cited by 42
“In addition, miRNA-21 was shown to be involved in cardiac remodeling andmyocardial dysfunction induced by pressure-overload (Thum et al., 2008).”
BackgroundmiRNA interventions serve as ‘magic bullets’ in the reversal of glioblastoma hallmarks
Chen, L., & Kang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.5926 · Cited by 42
“The antagomiRs are well tolerated, and function satisfactorily both in vitro and in vivo, indicating a more generally accepted complementarity-based method for miRNA silencing [96, 97].”
BackgroundEnhancing adoptive T cell immunotherapy with microRNA therapeutics
Ji, Y., Hocker, J. D., & Gattinoni, L. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.006 · Cited by 46
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.